



Pascal Biosciences Announces New OTC Markets Trading Symbol PSCBF

VANCOUVER, BRITISH COLUMBIA, June 1, 2021- Pascal Biosciences Inc. (“**Pascal**” or the “**Company**”) (TSXV:PAS) (OTC:PSCBF, previously BIMUF), has today received a new Over The Counter (OTC) trading symbol following acceptance of Form 211 by the US Financial Industry Regulatory Authority (FINRA). The new symbol is PSCBF and better reflects the company name PaSCal Biosciences.

In addition, Pascal announced the Board of Directors has appointed Mark van der Horst as President. Mr. van der Horst has been the president of Gale Capital Corporation (Gale) since 1993. Gale has worked with numerous public companies in both Canada and the United States as a capital markets advisor. Most recently, Mark was CEO of two recently listed CSE companies, EyeFi Group Technologies Inc. (CSE:EGTI) and EonX Technologies Inc. (CSE:EONX) and was instrumental in their organization, listing and financing.

“We are making a concerted effort to increase our corporate communications in both Canada and the US. Further to that point, we are excited to welcome Mark van der Horst onboard as President. Mr. van der Horst brings over 30 years of North American capital markets experience and will be instrumental in creating greater investor awareness for Pascal.” said CEO Patrick Gray.

FINRA is the US regulator responsible for OTC markets including the OTCBB and Pink Sheets. A company must file Form 211 with FINRA to comply with SEC Rule 15c2-11, which covers the requirements necessary for the initiation of electronic quotation of securities in the OTC Markets. The completed Form 211 provides basic corporate information for review by FINRA.

ABOUT PASCAL BIOSCIENCES INC.

Pascal is a biotechnology company targeting innovative therapies for serious diseases, including COVID-19. Pascal is also developing treatments for cancer with targeted therapies for acute lymphoblastic leukemia and cannabinoid-based therapeutics. Pascal's leading portfolio also comprises a small molecule therapeutic, PAS-403, that is advancing into clinical trials for the treatment of glioblastoma, and PAS-393, an immuno-stimulatory cannabinoid to be used in combination with checkpoint inhibitor therapy which is being developed collaboratively with SoRSE Technology.

To learn more, visit: <https://www.pascalbiosciences.com/>.

On Behalf of the Board of Directors
Dr. Patrick W. Gray, CEO

Company Contact:

Dr. Patrick Gray

Investors:

invest@pascalbiosciences.com

Tel: 206-221-3443

Forward-Looking Statements**DISCLAIMER**

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.

“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release”